Home›Articles›A Rejected Trial Design Held Tivozanib Back for Eight YearsArticleA Rejected Trial Design Held Tivozanib Back for Eight YearsArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnTivozanib, Drugs and Medicinal Substances Well-attested SourcesTivozanib (Wikipedia)tier 2WikipediaHistory, FDA advisory committee voteQuote, History, FDA advisory committee votevoted in May 2013 13 to 1 against recommending approval of tivozanib for renal cell carcinomaView the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.